Paradigm Biopharmaceuticals

Sign up to get the latest news, announcements and updates from Paradigm delivered straight to your inbox, and be the first to hear as our research advances.

Home

About us

Pipeline

Clinical Trials

Peer-Reviewed Publications

Cardiovascular

Respiratory

Lysosomal Storage Diseases

Inflammatory Arthritis

Osteoarthritis

Our Board

Executive Team

Corporate Governance

Analyst Reports

Market Data

Webinars

Announcements

News & Videos

Contact

Archivo

PAR_update_08_10_2025[5].pdf

Research update published by Lodge Partners on 8th October 2025. Paradigm Biopharmaceuticals has commenced dosing patients in its global Phase 3 trial (PARA_OA_012) of injectable pentosan polysulfate sodium (Zilosul®) for knee osteoarthritis. Fifteen sites in Australia and 50 in the US have been selected, with site activation expected to ramp up by end of October. Interim analysis is planned for mid-2026, a key catalyst for the program. The trial is powered at an effect size of 0.3, providing strong confidence in detecting efficacy consistent with prior Phase 2 results.

Paradigm Biopharmaceuticals (ASX:PAR) — Lodge Partners Research Update (8 Oct 2025)